Drugs / Nordilet®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03223025 | Mar 2016 → Feb 2017 | pituitary deficiency | Cinnagen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nordilet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03223025 ↗ |
| Known as | recombinant human growth hormone (Nordilet) | “recombinant human growth hormone (Nordilet®)” NCT03223025 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human growth hormone (Nordilet®)” NCT03223025 ↗ |
| Route | Subcutaneous | “Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months.” NCT03223025 ↗ |